All In MedTech

FDA Clearance Tracker · P990017

ANCURE(TM) TUBE SYSTEM, ANCURE(TM) BIFURCATED SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 28, 1999 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Sep 28, 1999

Approval withdrawn

Time to decision

197 days

Received Mar 15, 1999. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P990017
Device name
ANCURE(TM) TUBE SYSTEM, ANCURE(TM) BIFURCATED SYSTEM
Applicant location
St Paul, MN
Received
Mar 15, 1999
Decided
Sep 28, 1999
Decision
Approval withdrawn
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
33 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MIH

FDA's approval statement

As written in FDA's record.

Approval for the ANCURE Tube and Bifurcated Systems and the ANCURE Iliac Balloon Catheter (9 mm to 14 mm sizes). This device has the following indications for use: The ANCURE(TM) Tube System is indicated for the endovascular treatment of infrarenal abdominal aortic aneurysms (AAA) in patients having adequate iliac/femoral access, infrarenal non-aneurysmal neck length of at least 15 mm and a diameter of no greater than 26mm, distal segment neck length of 12mm and diameter of no greater than 26mm, and morphology suitable for endovascular repair. The ANCURE(TM) Bifurcated System is indicated for the endovascular treatment of infrarenal abdominal aortic or aorto-iliac aneurysms in patients having adequate iliac/femoral access, infrarenaln non-aneurysmal neck length of at least 15mm and a diameter of no greater than 26mm, distal segment lengths of at least 20mm and diameters no greater than 13.4mm, and morphology suitable for endovascular repair. The ANCURE(TM) Iliac Balloon Catheter is indicated for use in securing the attachment systems in the iliac arteries and/or to expand vascular prosthesis limbs of the ANCURE(TM) ENDOGRAFT(R) Vascular Prosthesis.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code MIH (SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.